In NAFLD, bile acids can improve inflammation and glucolipid metabolism through the regulation of FXR and TGR5 expression and their downstream signaling pathways [35]. The gene discussed is GPBAR1; the disease is metabolic dysfunction-associated steatotic liver disease.